Piper Sandler Begins Coverage on Kestra Medical Technologies (NASDAQ:KMTS)

Investment analysts at Piper Sandler began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report issued on Monday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $27.00 price target on the stock. Piper Sandler’s target price indicates a potential upside of 9.85% from the stock’s current price.

KMTS has been the topic of several other research reports. Stifel Nicolaus initiated coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued a “buy” rating and a $28.00 price objective on the stock. The Goldman Sachs Group began coverage on shares of Kestra Medical Technologies in a research note on Monday. They issued a “neutral” rating and a $24.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Kestra Medical Technologies Trading Down 1.4 %

NASDAQ:KMTS opened at $24.58 on Monday. Kestra Medical Technologies has a fifty-two week low of $20.00 and a fifty-two week high of $25.98.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.